Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Return on Capital Employed for 10 consecutive years, with 0.55% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 9.0% to 0.55% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.55%, a 9.0% decrease, with the full-year FY2025 number at 0.47%, down 1.0% from a year prior.
  • Return on Capital Employed was 0.55% for Q4 2025 at Ultragenyx Pharmaceutical, up from 0.6% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.2% in Q1 2021 to a low of 0.61% in Q2 2023.
  • A 5-year average of 0.45% and a median of 0.47% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: increased 25bps in 2021, then decreased -21bps in 2022.
  • Ultragenyx Pharmaceutical's Return on Capital Employed stood at 0.29% in 2021, then tumbled by -70bps to 0.49% in 2022, then dropped by -7bps to 0.52% in 2023, then increased by 13bps to 0.46% in 2024, then decreased by -20bps to 0.55% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Return on Capital Employed are 0.55% (Q4 2025), 0.6% (Q3 2025), and 0.5% (Q2 2025).